SLC5A2 and glomerular disorder: Given that obesity worsens outcomes of other glomerular disease beyond ORG, it is noteworthy that a recent trial of SGLT2 inhibition in glomerulonephritis patients showed higher proteinuria reduction with SGLT2 inhibition in patients with increased BMI (36, 75).